| DrugRepV_5245 | Cytarabine | NA | Leukemia | Variola virus | Harvey | NA | Focus forming assay | Decrease (82.3 %) | Approved | 198636 |
| DrugRepV_5246 | Cytarabine | NA | Leukemia | Variola virus | Harvey | NA | Focus forming assay | Decrease (30.2 %) | Approved | 198636 |
| DrugRepV_5247 | 6-Azauridine | NA | Cancer | Variola virus | Harvey | NA | Focus forming assay | Decrease (1.2 %) | NA | 198636 |
| DrugRepV_5248 | Cytarabine | NA | Leukemia | Variola virus | Yamamoto P | NA | Focus forming assay | Decrease (66.1 %) | Approved | 198636 |
| DrugRepV_5249 | 6-Azauridine | NA | Cancer | Variola virus | Yamamoto P | NA | Focus forming assay | Decrease (2.9 %) | NA | 198636 |
| DrugRepV_5250 | Cytarabine | NA | Leukemia | Variola virus | Butler | NA | Focus forming assay | Decrease (44.4 %) | Approved | 198636 |
| DrugRepV_5251 | 6-Azauridine | NA | Cancer | Variola virus | Butler | NA | Focus forming assay | No significant effect (No inhibition %) | NA | 198636 |
| DrugRepV_5252 | Rifampicin | Antiinfectives For Systemic Use | Tuberculosis and Tuberculosis-related mycobacterial infections | Variola virus | Butler | NA | Plaque assay | Decrease (Complete inhibition Plaque size) | Approved | 4321450 |
| DrugRepV_5253 | beta-D-cyclopentenyl cytosine | NA | NA | Variola virus | Bangladesh 1975 | NA | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_5254 | beta-D-cyclopentenyl cytosine | NA | NA | Variola virus | 7124 | NA | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_5255 | beta-D-cyclopentenyl-5-iodocytidine | NA | NA | Variola virus | Bangladesh 1975 | NA | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_5256 | beta-D-cyclopentenyl-5-iodocytidine | NA | NA | Variola virus | 7124 | NA | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_5257 | beta-D-Cyclopentenyl-5-chlorocytidine | NA | NA | Variola virus | Bangladesh 1975 | NA | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_5258 | beta-D-Cyclopentenyl-5-chlorocytidine | NA | NA | Variola virus | 7124 | NA | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_5259 | beta-D-cyclopentenyl-5-bromocytidine | NA | NA | Variola virus | Bangladesh 1975 | NA | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_5260 | beta-D-cyclopentenyl-5-bromocytidine | NA | NA | Variola virus | 7124 | NA | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_7519 | Rifampicin | Antiinfectives For Systemic Use | Tuberculosis and Tuberculosis-related mycobacterial infections | Vaccinia virus | NA |  | Plaque assay | Decrease (Complete inhibition Plaque size) | Approved | 4321450 |
| DrugRepV_7520 | beta-D-cyclopentenyl cytosine | NA | NA | Vaccinia virus | Copenhagen | | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_7521 | beta-D-cyclopentenyl-5-iodocytidine | NA | NA | Vaccinia virus | Copenhagen | | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_7522 | beta-D-Cyclopentenyl-5-chlorocytidine | NA | NA | Vaccinia virus | Copenhagen | | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_7523 | beta-D-cyclopentenyl-5-bromocytidine | NA | NA | Vaccinia virus | Copenhagen | | NA | Decrease (50 %) | NA | 14604375 |
| DrugRepV_7524 | Quinacrine | NA | Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions | Vaccinia virus | NA | | NA | Decrease (50 %) | Investigational | 31307979 |
| DrugRepV_8133 | StemRegenin 1 | NA | NA | Vaccinia virus | NA | | NA | Decrease (68.1 %) | NA | 32708182 |
| DrugRepV_8134 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Vaccinia virus | NA | | NA | Decrease (43.7 %) | Approved | 32708182 |
| DrugRepV_8135 | ICG-001 | NA | NA | Vaccinia virus | NA | | NA | Decrease (80.9 %) | NA | 32708182 |
| DrugRepV_8136 | Nifuroxazide | Alimentary Tract And Metabolism | NA | Vaccinia virus | NA | | NA | Decrease (48.8 %) | Experimental | 32708182 |
| DrugRepV_8137 | NSC 319726 | NA | NA | Vaccinia virus | NA | | NA | Decrease (99.8 %) | NA | 32708182 |
| DrugRepV_8138 | Tenovin-1 | Anticancer | Cancer | Vaccinia virus | NA | | NA | Decrease (32 %) | NA | 32708182 |
| DrugRepV_8139 | RITA | NA | Cancer | Vaccinia virus | NA | | NA | Decrease (50.2 %) | NA | 32708182 |
| DrugRepV_8140 | Ciclopirox ethanolamine | Dermatologicals | Fungal infections | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Approved | 32708182 |
| DrugRepV_8141 | Econazole Nitrate | Dermatologicals | Fungal infections | Vaccinia virus | NA | | NA | Decrease (55.1 %) | Approved | 32708182 |
| DrugRepV_8142 | Miconazole Nitrate | Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System and Sex Hormones; Antiinfect | Fungal infections (Tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment o | Vaccinia virus | NA | | NA | Decrease (58.3 %) | Approved, Investigational, Vet approved | 32708182 |
| DrugRepV_8143 | Monensin sodium salt | NA | NA | Vaccinia virus | NA | | NA | Decrease (96.7 %) | Experimental, Vet approved | 32708182 |
| DrugRepV_8144 | Idoxuridine | Antiinfectives For Systemic Use | Keratoconjunctivitis and Keratitis caused by herpes simplex virus | Vaccinia virus | NA | | NA | Decrease (85.8 %) | Approved, Investigational | 32708182 |
| DrugRepV_8145 | 3-Deazaneplanocin A | NA | NA | Vaccinia virus | NA | | NA | Decrease (76.8 %) | NA | 32708182 |
| DrugRepV_8146 | Fludarabine | Antineoplastic and Immunomodulating Agents | Hematological malignancies | Vaccinia virus | NA | | NA | Decrease (99.1 %) | Approved | 32708182 |
| DrugRepV_8147 | Clofarabine | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Approved | 32708182 |
| DrugRepV_8148 | Azaguanine-8 | NA | NA | Vaccinia virus | NA | | NA | Decrease (12.7 %) | Experimental | 32708182 |
| DrugRepV_8149 | Cytarabine | NA | Leukemia | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Approved | 32708182 |
| DrugRepV_8150 | Gemcitabine | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Approved | 32708182 |
| DrugRepV_8151 | Cyclocytidine Hydrochloride | NA | NA | Vaccinia virus | NA | | NA | Decrease (99.8 %) | NA | 32708182 |
| DrugRepV_8152 | Trifluridine | Sensory Organ | Primary keratoconjunctivitis and Herpes simplex keratitis | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Approved | 32708182 |
| DrugRepV_8153 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Approved | 32708182 |
| DrugRepV_8154 | Floxuridine | Anticancer | Gastrointestinal adenocarcinomas | Vaccinia virus | NA | | NA | Decrease (62.6 %) | Approved | 32708182 |
| DrugRepV_8155 | Abitrexate | Antineoplastic and Immunomodulating Agents | Gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole and acute lymphocytic leukemia | Vaccinia virus | NA | | NA | Decrease (62.2 %) | Approved | 32708182 |
| DrugRepV_8156 | Triapine | NA | Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Investigational | 32708182 |
| DrugRepV_8157 | Vidarabine | Antiinfectives For Systemic Use; Sensory Organ | Viral infections (Chickenpox, Herpes simplex, Zoster and varicella zoster) | Vaccinia virus | NA | | NA | Decrease (99.7 %) | Approved | 32708182 |
| DrugRepV_8158 | Apigenin | NA | NA | Vaccinia virus | NA | | NA | Decrease (54.8 %) | Experimental | 32708182 |
| DrugRepV_8159 | Avasimibe | NA | Peripheral vascular disease | Vaccinia virus | NA | | NA | Decrease (50.9 %) | Investigational | 32708182 |
| DrugRepV_8160 | Cyclosporin A | NA | Bone marrow transplant rejection | Vaccinia virus | NA | | NA | Decrease (67.2 %) | Approved, Investigational, Vet approved | 32708182 |
| DrugRepV_8161 | ML130 | NA | NA | Vaccinia virus | NA | | NA | Decrease (35.9 %) | NA | 32708182 |
| DrugRepV_8162 | PAC-1 | NA | Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers | Vaccinia virus | NA | | NA | Decrease (95.5 %) | Investigational | 32708182 |
| DrugRepV_8163 | ABT-263 | NA | Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies | Vaccinia virus | NA | | NA | Decrease (33.1 %) | Investigational | 32708182 |
| DrugRepV_8164 | ABT-737 | NA | NA | Vaccinia virus | NA | | NA | Decrease (26.6 %) | NA | 32708182 |
| DrugRepV_8165 | PF-2545920 | NA | NA | Vaccinia virus | NA | | NA | Decrease (33.7 %) | NA | 32708182 |
| DrugRepV_8166 | Cladribine | Antineoplastic and Immunomodulating Agents | Lymphoproliferative diseases | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Approved | 32708182 |
| DrugRepV_8167 | Adefovir dipivoxil | Antiinfectives For Systemic Use | Hepatitis B virus | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Approved | 32708182 |
| DrugRepV_8168 | TPCA-1 | NA | NA | Vaccinia virus | NA | | NA | Decrease (78.5 %) | NA | 32708182 |
| DrugRepV_8169 | Mycophenolic Acid | Immunosuppressant | Organ rejection (immunosuppressants) | Vaccinia virus | NA | | NA | Decrease (96.7 %) | Approved, Investigational | 32708182 |
| DrugRepV_8170 | PTC-209 | NA | NA | Vaccinia virus | NA | | NA | Decrease (90.7 %) | NA | 32708182 |
| DrugRepV_8171 | Selisistat | NA | NA | Vaccinia virus | NA | | NA | Decrease (30.5 %) | NA | 32708182 |
| DrugRepV_8172 | Salinomycin | NA | NA | Vaccinia virus | NA | | NA | Decrease (92.5 %) | Vet approved | 32708182 |
| DrugRepV_8173 | Dapivirine | NA | Acquired immunodeficiency syndrome | Vaccinia virus | NA | | NA | Decrease (41.7 %) | Investigational | 32708182 |
| DrugRepV_8174 | CCG 50014 | NA | NA | Vaccinia virus | NA | | NA | Decrease (35.8 %) | NA | 32708182 |
| DrugRepV_8175 | Mocetinostat | NA | Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma | Vaccinia virus | NA | | NA | Decrease (46.9 %) | Investigational | 32708182 |
| DrugRepV_8176 | Atorvastatin Calcium | Cardiovascular agents | Coronary heart disease | Vaccinia virus | NA | | NA | Decrease (25.4 %) | Approved | 32708182 |
| DrugRepV_8177 | UK 383367 | NA | NA | Vaccinia virus | NA | | NA | Decrease (17 %) | NA | 32708182 |
| DrugRepV_8178 | Lonafarnib | NA | Solid tumors, leukemia (unspecified), and lung cancer | Vaccinia virus | NA | | NA | Decrease (36.2 %) | Investigational | 32708182 |
| DrugRepV_8179 | BX-912 | NA | NA | Vaccinia virus | NA | | NA | Decrease (42.3 %) | NA | 32708182 |
| DrugRepV_8180 | URB597 | NA | NA | Vaccinia virus | NA | | NA | Decrease (21.7 %) | NA | 32708182 |
| DrugRepV_8181 | Anagrelide HCl | NA | NA | Vaccinia virus | NA | | NA | Decrease (58.4 %) | NA | 32708182 |
| DrugRepV_8182 | Drospirenone | Genito Urinary System and Sex Hormones | Contraception | Vaccinia virus | NA | | NA | Decrease (57.4 %) | Approved | 32708182 |
| DrugRepV_8183 | Ethinyl estradiol | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (53.3 %) | Approved | 32708182 |
| DrugRepV_8184 | Norethindrone | Gynaecological-agents | Secondary amenorrhea | Endometriosis | Abnormal uterine bleeding | Vaccinia virus | NA | | NA | Decrease (48.4 %) | Approved | 32708182 |
| DrugRepV_8185 | Ganetespib | NA | BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome | Vaccinia virus | NA | | NA | Decrease (99.7 %) | Investigational | 32708182 |
| DrugRepV_8186 | PF-04929113 | NA | Cancer/tumors | Vaccinia virus | NA | | NA | Decrease (99.4 %) | Investigational | 32708182 |
| DrugRepV_8187 | NMS-E973 | NA | NA | Vaccinia virus | NA | | NA | Decrease (99.1 %) | NA | 32708182 |
| DrugRepV_8188 | XL888 | NA | NA | Vaccinia virus | NA | | NA | Decrease (99.6 %) | NA | 32708182 |
| DrugRepV_8189 | Tanespimycin | NA | Leukemia (myeloid) and solid tumors. | Vaccinia virus | NA | | NA | Decrease (99.4 %) | Investigational | 32708182 |
| DrugRepV_8190 | VER-49009 | NA | NA | Vaccinia virus | NA | | NA | Decrease (98.9 %) | NA | 32708182 |
| DrugRepV_8191 | SNX2112 | NA | NA | Vaccinia virus | NA | | NA | Decrease (99.4 %) | NA | 32708182 |
| DrugRepV_8192 | BIIB021 | NA | Tumors and Lymphoma | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Investigational | 32708182 |
| DrugRepV_8193 | AT13387 | Antiinfectives For Systemic Use | Hepatitis C virus | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Phase III | 32708182 |
| DrugRepV_8194 | NVP-BEP800 | NA | NA | Vaccinia virus | NA | | NA | Decrease (98.8 %) | NA | 32708182 |
| DrugRepV_8195 | AUY922 | NA | Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms | Vaccinia virus | NA | | NA | Decrease (99.8 %) | Investigational | 32708182 |
| DrugRepV_8196 | KW-2478 | NA | NA | Vaccinia virus | NA | | NA | Decrease (92.7 %) | NA | 32708182 |
| DrugRepV_8197 | Vincristine | Antineoplastic and Immunomodulating Agents | Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors) | Vaccinia virus | NA | | NA | Decrease (96.6 %) | Approved | 32708182 |
| DrugRepV_8198 | ABT-751 | NA | Lung Cancer | Vaccinia virus | NA | | NA | Decrease (81.5 %) | Investigational | 32708182 |
| DrugRepV_8199 | Epothilone A | NA | NA | Vaccinia virus | NA | | NA | Decrease (27.3 %) | NA | 32708182 |
| DrugRepV_8200 | Amygdalin | NA | NA | Vaccinia virus | NA | | NA | Decrease (58.3 %) | NA | 32708182 |
| DrugRepV_8201 | Kaempferol | NA | NA | Vaccinia virus | NA | | NA | Decrease (64.7 %) | NA | 32708182 |
| DrugRepV_8202 | ENMD-2076 | NA | Breast cancer, leukemia (unspecified), lung cancer, and solid tumors | Vaccinia virus | NA | | NA | Decrease (72.3 %) | Investigational | 32708182 |
| DrugRepV_8203 | AMG-900 | NA | NA | Vaccinia virus | NA | | NA | Decrease (50.4 %) | NA | 32708182 |
| DrugRepV_8204 | MLN8054 | NA | Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies | Vaccinia virus | NA | | NA | Decrease (36.2 %) | Investigational | 32708182 |
| DrugRepV_8205 | Ibrutinib | NA | Mantle cell lymphoma | Vaccinia virus | NA | | NA | Decrease (74.9 %) | Approved | 32708182 |
| DrugRepV_8206 | CNX-774 | NA | NA | Vaccinia virus | NA | | NA | Decrease (70 %) | NA | 32708182 |
| DrugRepV_8207 | AR-A014418 | NA | NA | Vaccinia virus | NA | | NA | Decrease (47.9 %) | Experimental | 32708182 |
| DrugRepV_8208 | CGP 57380 | NA | NA | Vaccinia virus | NA | | NA | Decrease (58.1 %) | NA | 32708182 |
| DrugRepV_8209 | Genistein | Antihelmintic | Prostate cancer | Vaccinia virus | NA | | NA | Decrease (40.6 %) | Investigational | 32708182 |
| DrugRepV_8210 | HMN-214 | NA | NA | Vaccinia virus | NA | | NA | Decrease (58.9 %) | NA | 32708182 |
| DrugRepV_8211 | TG003 | NA | NA | Vaccinia virus | NA | | NA | Decrease (46.7 %) | NA | 32708182 |
| DrugRepV_8212 | Skepinone-L | NA | NA | Vaccinia virus | NA | | NA | Decrease (47.1 %) | NA | 32708182 |
| DrugRepV_8213 | TAK-632 | NA | NA | Vaccinia virus | NA | | NA | Decrease (65.2 %) | NA | 32708182 |
| DrugRepV_8214 | YM201636 | NA | NA | Vaccinia virus | NA | | NA | Decrease (56.3 %) | NA | 32708182 |
| DrugRepV_8215 | MK-2461 | NA | NA | Vaccinia virus | NA | | NA | Decrease (57 %) | NA | 32708182 |
| DrugRepV_8216 | OSI-930 | Anticancer | Solid tumors | Vaccinia virus | NA | | NA | Decrease (43.5 %) | Investigational | 32708182 |
| DrugRepV_8217 | SP600125 | NA | NA | Vaccinia virus | NA | | NA | Decrease (50.5 %) | NA | 32708182 |
| DrugRepV_8218 | SKI II | NA | NA | Vaccinia virus | NA | | NA | Decrease (65.1 %) | NA | 32708182 |
| DrugRepV_8219 | PKI-402 | NA | NA | Vaccinia virus | NA | | NA | Decrease (44.9 %) | NA | 32708182 |
| DrugRepV_8220 | BEZ235 | NA | Cancer, Solid Tumor, Renal Cancer, Breast Cancer, and Cowden Syndrome | Vaccinia virus | NA | | NA | Decrease (37.4 %) | Investigational | 32708182 |
| DrugRepV_8221 | WYE-125132 | NA | NA | Vaccinia virus | NA | | NA | Decrease (67.6 %) | NA | 32708182 |
| DrugRepV_8222 | OSI-027 | NA | NA | Vaccinia virus | NA | | NA | Decrease (68.3 %) | Investigational | 32708182 |
| DrugRepV_8223 | Torin 1 | NA | NA | Vaccinia virus | NA | | NA | Decrease (57.3 %) | NA | 32708182 |
| DrugRepV_8224 | Ku-0063794 | NA | NA | Vaccinia virus | NA | | NA | Decrease (55.3 %) | NA | 32708182 |
| DrugRepV_8225 | AZD2014 | NA | Advanced Gastric Adenocarcinoma | Vaccinia virus | NA | | NA | Decrease (70.3 %) | Investigational | 32708182 |
| DrugRepV_8226 | Nocodazole | Anticancer | NA | Vaccinia virus | NA | | NA | Decrease (76.2 %) | Experimental | 32708182 |
| DrugRepV_8227 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (74.2 %) | Approved | 32708182 |
| DrugRepV_8228 | KX2-391 | NA | Colon cancer | Pancreatic cancer | Prostate cancer | Breast cancer | Vaccinia virus | NA | | NA | Decrease (65.1 %) | Investigational | 32708182 |
| DrugRepV_8229 | Bosutinib | Antineoplastic and Immunomodulating Agents | Chronic myelogenous leukemia (CML) | Vaccinia virus | NA | | NA | Decrease (81.8 %) | Approved | 32708182 |
| DrugRepV_8230 | PP1 | NA | NA | Vaccinia virus | NA | | NA | Decrease (35.8 %) | NA | 32708182 |
| DrugRepV_8231 | AZ 960 | NA | NA | Vaccinia virus | NA | | NA | Decrease (82.1 %) | NA | 32708182 |
| DrugRepV_8232 | LY2784544 | NA | Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders | Vaccinia virus | NA | | NA | Decrease (65.7 %) | Investigational | 32708182 |
| DrugRepV_8233 | WHI-P154 | NA | NA | Vaccinia virus | NA | | NA | Decrease (66.3 %) | NA | 32708182 |
| DrugRepV_8234 | Cyt387 | NA | Polycythemia Vera, Primary Myelofibrosis, Post-Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis (PMF) | Vaccinia virus | NA | | NA | Decrease (45.2 %) | Investigational | 32708182 |
| DrugRepV_8235 | KPT-276 | NA | NA | Vaccinia virus | NA | | NA | Decrease (27.6 %) | NA | 32708182 |
| DrugRepV_8236 | KPT-185 | NA | NA | Vaccinia virus | NA | | NA | Decrease (26.2 %) | NA | 32708182 |
| DrugRepV_8237 | Phloretin | NA | NA | Vaccinia virus | NA | | NA | Decrease (-27 %) | Experimental | 32708182 |
| DrugRepV_8238 | Ivacaftor | Respiratory System | Cystic fibrosis | Vaccinia virus | NA | | NA | Decrease (75.5 %) | Approved | 32708182 |
| DrugRepV_8239 | Tolbutamide | Alimentary Tract and Metabolism | Type 2 Diabetes Mellitus | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Approved, Investigational | 32708182 |
| DrugRepV_8240 | Fexofenadine Hydrochloride | Respiratory System | Allergic rhinitis | Vaccinia virus | NA | | NA | Decrease (10.5 %) | Approved | 32708182 |
| DrugRepV_8241 | Bergapten | Dermatologicals | Severe Generalized Atopic Dermatitis | Vaccinia virus | NA | | NA | Decrease (7.6 %) | Investigational | 32708182 |
| DrugRepV_8242 | SC144 | NA | NA | Vaccinia virus | NA | | NA | Decrease (98.4 %) | NA | 32708182 |
| DrugRepV_8243 | Daidzein | NA | Dietary supplement | Vaccinia virus | NA | | NA | Decrease (32.2 %) | Experimental | 32708182 |
| DrugRepV_8244 | Delanzomib | NA | Solid Tumors, Multiple Myeloma, and Lymphoma, Non-Hodgkin. | Vaccinia virus | NA | | NA | Decrease (99.7 %) | Investigational | 32708182 |
| DrugRepV_8245 | MLN9708 | NA | Multiple myeloma | Vaccinia virus | NA | | NA | Decrease (99.6 %) | Approved, Investigational | 32708182 |
| DrugRepV_8246 | Oprozomib | NA | NA | Vaccinia virus | NA | | NA | Decrease (99.5 %) | Investigational | 32708182 |
| DrugRepV_8247 | MG-132 | NA | NA | Vaccinia virus | NA | | NA | Decrease (98.9 %) | NA | 32708182 |
| DrugRepV_8248 | MLN2238 | NA | Multiple myeloma | Vaccinia virus | NA | | NA | Decrease (99.7 %) | Approved, Investigational | 32708182 |
| DrugRepV_8249 | ONX-0914 | NA | NA | Vaccinia virus | NA | | NA | Decrease (99.5 %) | NA | 32708182 |
| DrugRepV_8250 | Amonafide | NA | Breast cancer, ovarian cancer, and prostate cancer | Vaccinia virus | NA | | NA | Decrease (99.3 %) | Investigational | 32708182 |
| DrugRepV_8251 | Teniposide | Antineoplastic and Immunomodulating Agents | Acute lymphoblastic leukaemia | Vaccinia virus | NA | | NA | Decrease (97.9 %) | Approved | 32708182 |
| DrugRepV_8252 | Etoposide | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (60.1 %) | Approved | 32708182 |
| DrugRepV_8253 | Golvatinib | NA | Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | Vaccinia virus | NA | | NA | Decrease (79.8 %) | Investigational | 32708182 |
| DrugRepV_8254 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Vaccinia virus | NA | | NA | Decrease (72.6 %) | Approved, Investigational | 32708182 |
| DrugRepV_8255 | AG 1296 | NA | NA | Vaccinia virus | NA | | NA | Decrease (53.2 %) | NA | 32708182 |
| DrugRepV_8256 | NVP-TAE226 | NA | NA | Vaccinia virus | NA | | NA | Decrease (91.5 %) | NA | 32708182 |
| DrugRepV_8257 | Cabozantinib malate | NA | Metastatic medullary thyroid cancer | Vaccinia virus | NA | | NA | Decrease (79.3 %) | NA | 32708182 |
| DrugRepV_8258 | XL-184 | NA | Thyroid cancer | Vaccinia virus | NA | | NA | Decrease (64.2 %) | Approved, Investigational | 32708182 |
| DrugRepV_8259 | Linifanib | NA | NA | Vaccinia virus | NA | | NA | Decrease (60.5 %) | NA | 32708182 |
| DrugRepV_8260 | TKI-258 | NA | Multiple myeloma and solid tumors | Vaccinia virus | NA | | NA | Decrease (67.6 %) | Investigational | 32708182 |
| DrugRepV_8261 | AZD4547 | NA | Cancer | Vaccinia virus | NA | | NA | Decrease (81.5 %) | Investigational | 32708182 |
| DrugRepV_8262 | AG-1024 | NA | NA | Vaccinia virus | NA | | NA | Decrease (71.8 %) | NA | 32708182 |
| DrugRepV_8263 | BMS-754807 | NA | Solid Tumors | Vaccinia virus | NA | | NA | Decrease (61.8 %) | Investigational | 32708182 |
| DrugRepV_8264 | Afatinib | Antineoplastic And Immunomodulating Agents | Metastatic non-small cell lung cancer | Vaccinia virus | NA | | NA | Decrease (95.2 %) | Approved | 32708182 |
| DrugRepV_8265 | Butein | NA | NA | Vaccinia virus | NA | | NA | Decrease (62.6 %) | NA | 32708182 |
| DrugRepV_8266 | CO-1686 (AVL-301) | NA | Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer | Vaccinia virus | NA | | NA | Decrease (74.3 %) | NA | 32708182 |
| DrugRepV_8267 | PD168393 | NA | NA | Vaccinia virus | NA | | NA | Decrease (67.2 %) | Experimental | 32708182 |
| DrugRepV_8268 | PD153035 HCl | NA | NA | Vaccinia virus | NA | | NA | Decrease (74.7 %) | NA | 32708182 |
| DrugRepV_8269 | Gefitinib | Antineoplastic and Immunomodulating Agents | Non-small cell lung cancer | Vaccinia virus | NA | | NA | Decrease (91.2 %) | Approved, Investigational | 32708182 |
| DrugRepV_8270 | Desmethyl Erlotinib | NA | Cancer | Vaccinia virus | NA | | NA | Decrease (75.5 %) | Approved, Investigational | 32708182 |
| DrugRepV_8271 | OSI-420 | NA | NA | Vaccinia virus | NA | | NA | Decrease (46.7 %) | NA | 32708182 |
| DrugRepV_8272 | Neratinib | Antineoplastic And Immunomodulating Agents | Breast cancer | Vaccinia virus | NA | | NA | Decrease (56.7 %) | Approved, Investigational | 32708182 |
| DrugRepV_8273 | Erlotinib Hydrochloride | Antineoplastic and Immunomodulating Agents | Cancer | Vaccinia virus | NA | | NA | Decrease (66.8 %) | Approved | 32708182 |
| DrugRepV_8274 | WZ8040 | NA | NA | Vaccinia virus | NA | | NA | Decrease (96.4 %) | NA | 32708182 |